CN100420448C - Health-care food with function for improving immunity and its prepn. method - Google Patents
Health-care food with function for improving immunity and its prepn. method Download PDFInfo
- Publication number
- CN100420448C CN100420448C CNB2005100956302A CN200510095630A CN100420448C CN 100420448 C CN100420448 C CN 100420448C CN B2005100956302 A CNB2005100956302 A CN B2005100956302A CN 200510095630 A CN200510095630 A CN 200510095630A CN 100420448 C CN100420448 C CN 100420448C
- Authority
- CN
- China
- Prior art keywords
- group
- cordyceps
- ganoderma
- health food
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses a health-care food for immunity enhancement and a preparation technology thereof. The health-care food is prepared from propolis, ganoderma extractives and caterpillar fungus mycelia. The health-care food has the advantages of preferable immunity enhancement function, high safety and simple and feasible preparation technology.
Description
Technical field
The invention belongs to field of health care food, relate to a kind of health food of enhancing immunity, the invention still further relates to the preparation technology of this health food.
Background technology
The propolis resin that to be Apis gather from positions such as the tree bud of plant, barks mixes the secretions with bodies of gland such as Apis lingual gland, wax glands again, a kind of colloid substance that is transformed through Apis processing.Apis is coated on the surface of whole Nidus Vespae with these materials, plays anticorrosion, antioxidation on the one hand, comes bonding Nidus Vespae on the other hand, and obstruction slit etc. can't grow numerous pathogenic bacterias in Nidus Vespae.Propolis can play comprehensive conditioning, the effect of balancing machine body immunity function, and put down in writing according to " China's book on Chinese herbal medicine ": propolis has good auxiliary treatment effect to diabetes, hyperlipidemia, hypertension, tumor, polyp, multiple inflammation, germ disease etc.
Ganoderma [Ganoderma Lucidum (Leyss ex Fr) kast] is called Ganoderma, Ganoderma lucidum seu Japonicum again, and Li Shizhen (1518-1593 A.D.) is thought Ganoderma " cure mainly deafness, sharp joint is protected refreshingly, and beneficial vital essence, hard muscles and bones, good color, clothes are made light of one's life by commiting suicide not oldly for a long time, prolong life, and treat asthenia, control hemorrhoid ".
Over nearly 40 years, Ganoderma has been carried out a large amount of scientific researches and clinical practice work, confirmed Ganoderma composition has polysaccharide, mainly contains immunoregulatory function, and detoxifcation is arranged, effect such as protects the liver.
Ganoderma has the effect of strengthening the body resistance to human body, various pharmacological activities is arranged, all can prove from the medical treatment of successive dynasties name medical drugs and modern age is clinical, every and poor blood circulation, body weakness, premunition decline diseases associated, Ganoderma all has certain therapeutic effect to it.It is raw material that this prescription is selected Ganoderma extract for use, and it is rich in functional components such as polysaccharide, has the function of enhancing immunity.
The Cordyceps mycelium invigorating the lung and the kidney, stops blooding, reduces phlegm at replenishing essence QI invigorating, antitussive and antiasthmatic.To weak and sickly, old, overtired powerful benefiting action, the immunization that can improve human body arranged.
Propolis adds Ganoderma extract and Cordyceps mycelium, has the effect of enhancing immunity, and, because the bacterium effect of supporting of propolis also plays a role to guaranteeing the quality of product.
Still do not adopt at present the health food of the human body immunity improving power of these three kinds of raw material prescription preparations.
List of references:
1, Lin Zhibin, the modern study of Ganoderma, publishing house of Beijing Medical University, March calendar year 2001.
2, State Administration of Traditional Chinese Medicine, " China's book on Chinese herbal medicine ", Shanghai science tech publishing house.
Summary of the invention
The health food that the purpose of this invention is to provide a kind of enhancing immunity.
A further object of the invention provides the preparation technology of above-mentioned health food.
The objective of the invention is to realize by following technical measures:
A kind of health food of enhancing immunity, its prescription contains the raw material of following weight portion:
Propolis 50-60 part, Ganoderma extract 30-40 part, Cordyceps mycelium 5-15 part.
Described health food, wherein Ganoderma extract prepares by following method: Ganoderma adds 8-12 times of water gaging after cutting into slices, and extracts 2-3 time, and each 4-6 hour, merge extractive liquid, concentrated the back spray drying; The prescription of Ganoderma extract is: polysaccharide 〉=8.0%, moisture≤8.0%, ash≤10.0%.The outward appearance of Ganoderma extract is the dark-brown powder, drying, and free from admixture has the intrinsic fragrance of Ganoderma.
Health food with enhancing immunity effect of the present invention can add any one adjuvant that pharmaceutically allows, its preparation can be any one dosage form that pharmaceutically allows, include but not limited to tablet, granule, capsule, oral liquid, syrup, pill etc., can also add the health food that other materials that do not weaken health food effect of the present invention are made complex function in the health food of the present invention.
The preparation technology of described health food comprises the following step:
Get Cordyceps mycelium by prescription and pulverize, cross 80 mesh sieves, with the Ganoderma extract mix homogeneously, 110-130 ℃ dry heat sterilization 1-2 hour, add again through pulverizing the propolis of 80 mesh sieves, mix homogeneously, common process are made required preparation.
Beneficial effect of the present invention:
Zoopery of the present invention:
One, material and method
1, sample: Cordyceps honeybee curing capsule, the 0.25g/ grain, the human body recommended intake is content net weight 1000mg/ people/day, and lot number 20040518 is provided by Nanjing Zhongke Biochemical Technology Co., Ltd.
2, laboratory animal:
The I group: 40 of 18.9-23.7g ICR healthy male mices, be divided into 4 groups at random, 10 every group, carry out dinitrofluorobenzene inducing mouse DTH test;
The II group: 40 of 18.5-23.4g healthy male mices, be divided into 4 groups at random, 10 every group, carry out Turnover of Mouse Peritoneal Macrophages and engulf the chicken red blood cell test;
The III group: 40 of 18.3-23.5g healthy male mices, be divided into 4 groups at random, 10 every group, carry out the clearance test of mice carbon;
The IV group: 40 of 20.0-23.9g healthy male mices, be divided into 4 groups at random, 10 every group, carry out mouse antibodies cellulation and half hemolysis value (HC
50) test;
The V group: 40 of 20.3-23.9g BALB/C healthy male mices, be divided into 4 groups at random, 10 every group, carry out the inductive mouse lymphocyte conversion of mice ConA, the test of NK cytoactive.
3, dosage:
According to everyone (by the 60kg weighing machine) recommended intake every day is 1000mg, be equivalent to 16.7mg/d/kgbw, press respectively 5 times of human body recommended intakes, 10 times, 30 times designs low (84mg/kgbw), in (167mg/kgbw), high (500mg/kgbw) three dosage groups, other establishes matched group (0mg/kgbw) and replaces being tried thing with sterilized water.Per os gives the thing that tried of mice corresponding dosage once a day, and the continuous irrigation stomach is surveyed every enhancing immunity functional parameter after 30 days.The mouse stomach amount is 10ml/kgbw.
4, main agents: dinitrofluorobenzene (DNFB), sheep red blood cell (SRBC) (SRBC), guinea pig serum, india ink, RPMI1640, ConA, MTT, isopropyl alcohol, SA buffer, Dou Shi reagent, YAC-1 cell, LDH substrate liquid.
5, key instrument: card punch, T1000 type electric animal balance, JA2003 type electronic balance, 722 type spectrophotometers, superclean bench, microplate reader, CO2 gas incubator.
6, test method: the enhancing immunity functional check method by " health food check with assessment technique standard-2003 edition " is carried out.
6.1 ConA inducing mouse splenocyte conversion test (mtt assay):
Each treated animal continuous irrigation stomach 30 days, animal is put to death in the cervical vertebra dislocation, and the aseptic spleen of getting places the little plate that fills an amount of aseptic Hank ' s liquid, grind spleen, make the individual cells suspension, filter, use Hank ' s liquid to wash 3 times through 200 eye mesh screens, each centrifugal 10min (1000r/min), then with cell suspension in 1ml RPMI1640 complete culture solution, the blue dyeing counting viable count of platform phenol (should more than 95%), adjusting cell concentration is 3 * 10
6Individual/ml.Divide two holes to add in 24 culture plates cell suspension, every hole 1ml, a hole adds 75 μ l ConA liquid, and another hole compares, and puts 5%CO
2Cultivate 72h in 37 ℃ of incubators.Cultivate and finish preceding 4h, supernatant 0.7ml is inhaled in every hole gently, adds the RPMI1640 culture fluid that 0.7ml does not contain calf serum, adds MTT (5mg/ml) 50 μ l/ holes simultaneously, continues to cultivate 4h.After cultivating end, every hole adds 1ml acid isopropyl alcohol, and the piping and druming mixing dissolves purple crystal fully.Lysate is moved in 96 well culture plates, wavelength 570nm, microplate reader is measured the optical density evaluation.
6.2 the tardy paraphilia reaction of dinitrofluorobenzene (DNFB) inducing mouse (DTH) (ear swelling method):
Each dosage group continuous irrigation stomach 30 days, every Mus cuts off belly wool with shears, the about 3cm * 3cm of scope, 50 μ l evenly smear sensitization with 1%DNFB solution.Evenly be applied in mouse right ear (two sides) with 1%DNFB solution 10 μ l after 5 days and attack, evenly be applied in mice left side ear (two sides) with the solution 10 μ l that do not contain DNFB simultaneously and compare.Attack back 24h cervical vertebra dislocation and put to death mice, cut left and right sides auricular concha, take off diameter 8mm auricle, weigh with card punch.Get mouse spleen, thymus simultaneously and weigh, calculate dirty/body ratio.
6.3 serum hemolysin is measured:
Each dosage group continuous irrigation stomach 30 days, sheep red blood cell (SRBC) (SRBC) suspension of preparation 2% (v/v), every Mus lumbar injection 0.2ml carries out immunity, extracts eyeball after 4 days and gets blood in centrifuge tube, places 1h, and the centrifugal 10min of 2000r/min separates and collection serum.After 200 times of dilutions of serum, the optical density value during by method of inspection working sample pipe and SRBC HD50.The amount of hemolysin is with half hemolysis value (HC
50) expression.
6.4 antibody-producting cell detects (Jerne improves slide method):
Each treated animal continuous irrigation stomach 30 days, sheep red blood cell (SRBC) (SRBC) the suspension 0.2ml of every Mus lumbar injection 2% (v/v) carries out immunity, and the dislocation of mice cervical vertebra is put to death after 4 days, take out spleen, be placed in the little plate that fills an amount of aseptic Hank ' s liquid, grind spleen, make cell suspension, filter through 200 eye mesh screens, centrifugal (1000r/min) 10min uses Hank ' s liquid to wash 2 times, at last with cell suspension in 5ml RPMI1640 culture fluid, the counting cells number, adjusting cell concentration is 5 * 10
6Individual/ml.After the culture medium heating for dissolving of top layer, put 45 ℃ of water bath heat preservations, mix with Hank ' the s liquid of equivalent pH7.2-7.4,2 times of concentration, the packing small test tube, every pipe 0.5ml adds 50 μ l, 10% (v/v again in pipe, with the preparation of SA liquid) SRBC, 20 μ l splenocyte suspensions (5 * 10
6Individual/ml), rapidly mixing is poured on the slide of brushing the agarose thin layer, treat that agar solidifies after, the slide level buckled be placed on the horse, put into CO
2Hatch 1.5h in the incubator, will join in the slide frame groove after the complement dilution in 1: 10 that prepare then, after continuing to hatch 1.5h, counting hemolysis plaque number.
6.5 mice carbon clearance test:
Each dosage group continuous irrigation stomach 30 days, every caudal vein injects the india ink (0.1ml/10gbw) of 3 times of dilutions, treats that prepared Chinese ink injects timing immediately.2min and 10min get blood 20 μ l from ophthalmic corner of the eyes venous plexus respectively behind the injection prepared Chinese ink, and it is added to 2ml 0.1%Na
2CO
3In the solution, with 722 spectrophotometers at 600nm wavelength place's photometry density value.
6.6 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell test (half intracorporal method):
Each treated animal continuous irrigation stomach 30 days, the chicken erythrocyte suspension of preparation 20% (v/v), every Mus lumbar injection 1ml, interval 30min, mice is put to death in the cervical vertebra dislocation, it is faced upward the position is fixed on the Mus plate, abdominal skin is cut off in the center, injects normal saline 2ml through the abdominal cavity, rotates Mus plate 1min, sucking-off abdominal cavity washing liquid 1ml then, average mark drips on 2 microscope slides, puts into the enamel box that is lined with wet gauze, 37 ℃ of incubation 30min of dislocation, rinsing in normal saline then, dry, fix, 4% (v/v) Giemsa-phosphate buffer dyeing 3min with 1: 1 acetone methanol solution, the rinsing of reuse distilled water is dried, and light microscopic is observed down.
6.7 the NK cytoactive is measured (determination of lactate dehydrogenase method):
Each treated animal continuous irrigation stomach 30 days, mice is put to death in the cervical vertebra dislocation, the aseptic spleen of getting, place the little plate that fills an amount of aseptic Hank ' s liquid, grind spleen, make single cell suspension, filter through 200 eye mesh screens, use Hank ' s liquid to wash 2 times, centrifugal at every turn (1000r/min) 10min abandons the supernatant friendship cytoplasm is upspring, and adds 0.5ml sterilization washing 20 seconds, add 0.5ml 2 times of Hank ' s liquid and 8ml Hank ' s liquid after the splitting erythrocyte again, centrifugal (1000r/min) 10min, the RPMI1640 complete culture solution that contains 10% calf serum with 1ml is resuspended, with 1% glacial acetic acid dilution back counting, the blue dyeing counting viable count of platform phenol (should more than 95%) is 2 * 10 with RPMI1640 complete culture solution adjustment cell concentration
7Individual/ml.
24h washes target cell (YAC-1 cell) cultivations of going down to posterity 3 times with Hank ' s liquid before using before the test, is 4 * 10 with RPMI1640 complete culture solution adjustment cell concentration
5Individual/ml.Getting each 100 μ l of YAC-1 cell and splenocyte (imitating target than 50: 1) adds in U type 96 well culture plates, YAC-1 cell nature release aperture adds YAC-1 cell and each 100 μ l of culture fluid, the maximum release aperture of YAC-1 cell adds YAC-1 cell and each 100 μ l of 1%NP40, above-mentioned every three parallel holes of all establishing are in 37 ℃, 5%CO
2Cultivate 4h in the incubator, then with 96 well culture plates with the centrifugal 5min of 1500r/min, draw at the bottom of the supernatant 100 μ l horizontalizations in 96 well culture plates in every hole, add LDH substrate liquid 100 μ l simultaneously, reaction 5min, every hole adds the HCl 30 μ l of 1mol/L, measures optical density value at microplate reader 490nm place.
7, raising condition: mice is that 18-22 ℃, relative humidity are to raise in the barrier system of 40-70% in temperature.
8, data analysis: with SPSS10.0 software each experiment initial data is carried out homogeneity test of variance, satisfy the neat data information that requires of variance and carry out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group; The data information of nonnormal distribution or heterogeneity of variance is carried out suitable variable conversion, wait to satisfy the normal state variance is neat require after, carry out statistical disposition with the data of changing gained.
Two, result:
1, Cordyceps honeybee curing capsule is to the influence of mice body weight
By table 1 as seen, the initial body weight of mice is compared with matched group in basic, normal, high three dosage groups, and there are no significant for difference.The initial body weight of mice is comparatively balanced between each group.Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, each dosage group body weight is carried out homogeneity test of variance, satisfy the requirement of homogeneity of variance, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Compared with matched group by visible basic, normal, high three the dosage groups of table 2 result, there are no significant for difference.Be that Cordyceps honeybee curing capsule does not have influence to weight of mice.
Table 1 is respectively organized initial body weight (n=10, the x ± SD) of mice
| Immunity I group | Immunity II group | Immunity III group | Immunity IV group | Immunity V group | |
| Matched group | 20.9±1.6 | 20.9±1.6 | 21.0±1.7 | 22.1±1.1 | 22.1±1.0 |
| Low dose group | 20.9±1.6 | 20.9±1.6 | 21.0±1.6 | 22.1±1.1 | 22.1±1.0 |
| Middle dosage group | 20.9±1.6 | 20.9±1.6 | 20.9±1.6 | 22.1±1.1 | 22.1±1.0 |
| High dose group | 20.9±1.7 | 20.9±1.6 | 20.9±1.6 | 22.1±1.2 | 22.1±1.1 |
Annotate: each is organized the P value and is 1.000.
Table 2 Cordyceps honeybee curing capsule is to the influence of mice body weight (n=10, x ± SD)
| Immunity I group | Immunity II group | Immunity III group | Immunity IV group | Immunity V group | |
| Matched group | 28.8±4.7 | 28.5±3.7 | 30.1±5.5 | 29.4±2.5 | 29.5±2.0 |
| Low dose group | 29.0±3.7 | 30.1±3.8 | 29.9±4.7 | 30.6±1.7 | 30.1±1.1 |
| Middle dosage group | 28.2±4.2 | 29.3±4.9 | 31.5±4.1 | 29.7±1.7 | 29.2±2.9 |
| High dose group | 26.3±4.2 | 31.8±4.4 | 29.8±5.8 | 29.6±2.7 | 30.2±1.8 |
Annotate: each organizes P＞0.05.
2, Cordyceps honeybee curing capsule is to the influence of thymus, spleen organ
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, the breast of being measured/body ratio, spleen/body ratio carry out normal distribution, homogeneity test of variance, satisfy the requirement of normal distribution, homogeneity of variance, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Compared with matched group by visible basic, normal, high three the dosage groups of table 3 result, there are no significant for difference.
Table 3 Cordyceps honeybee curing capsule is to the influence of thymus, spleen organ (n=10, x ± SD)
| Group | Thymus/body weight (mg/g) | P | Spleen/body weight (mg/g) | P |
| Matched group | 1.41±0.69 | 5.43±1.49 | ||
| Low dose group | 1.00±0.23 | 0.099 | 6.06±1.38 | 0.674 |
| Middle dosage group | 1.11±0.37 | 0.300 | 6.45±1.68 | 0.316 |
| High dose group | 1.03±0.28 | 0.143 | 6.00±1.46 | 0.736 |
3, Cordyceps honeybee curing capsule is to the influence of the inductive mouse spleen lymphocyte conversion of ConA
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, institute's measured value is carried out homogeneity test of variance, satisfy the homogeneity of variance requirement, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Add the ConA hole by visible basic, normal, high three the dosage group mices of table 4 result and be significantly higher than matched group with the difference that does not add ConA hole absorbance.
The influence that table 4 Cordyceps honeybee curing capsule transforms the inductive mouse spleen lymphocyte of ConA (n=10, x ± SD)
| Group | Add ConA hole and the difference that does not add ConA hole absorbance | P |
| Matched group | 0.029±0.016 | |
| Low dose group | 0.062±0.035 | 0.015 |
| Middle dosage group | 0.072±0.025 | 0.001 |
| High dose group | 0.068±0018 | 0.004 |
4, Cordyceps honeybee curing capsule is to the influence of DNFB inducing mouse DTH
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, institute's measured value is carried out homogeneity test of variance, satisfy the homogeneity of variance requirement, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Be significantly higher than matched group by the weightening finish of the visible high dose group mice of table 5 result auricular concha.
Table 5 Cordyceps honeybee curing capsule is to the influence of DNFB inducing mouse DTH (n=10, x ± SD)
| Group | The auricular concha weightening finish | P |
| Matched group | 5.0±3.2 | |
| Low dose group | 5.8±2.2 | 0.871 |
| Middle dosage group | 7.6±2.9 | 0.129 |
| High dose group | 9.6±3.2 | 0.003 |
5, Cordyceps honeybee curing capsule is to the influence of mice serum hemolysin formation
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, institute's measured value is carried out homogeneity test of variance, satisfy the homogeneity of variance requirement, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Be significantly higher than matched group by the visible high dose group mice serum of table 6 result hemolysin content.
The influence that table 6 Cordyceps honeybee curing capsule forms the mice serum hemolysin (n=10, x ± SD)
| Group | HC 50 | P |
| Matched group | 56±43 | |
| Low dose group | 107±54 | 0.082 |
| Middle dosage group | 108±57 | 0.076 |
| High dose group | 123±50 | 0.017 |
6, the influence of Cordyceps honeybee curing capsule antagonist cellulation (hemolysis plaque number)
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, institute's measured value is carried out normal distribution, homogeneity test of variance, satisfy the normal distribution requirement, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Be higher than matched group by visible middle and high two the dosage group mice hemolysis plaque digital display works of table 7 result.
Table 7 Cordyceps honeybee curing capsule is to the influence of mouse antibodies cellulation (hemolysis plaque number) (n=10, x ± SD)
| Group | Hemolysis plaque number (individual/10 6Splenocyte) | P |
| Matched group | 119±15 | |
| Low dose group | 163±53 | 0.217 |
| Middle dosage group | 204±61 | 0.006 |
| High dose group | 208±80 | 0.004 |
7, Cordyceps honeybee curing capsule is cleaned up the influence of effect to mice carbon
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, institute's measured value is carried out homogeneity test of variance, satisfy the homogeneity of variance requirement, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Compared with matched group by visible basic, normal, high three the dosage groups of table 8 result, there are no significant for difference.
Table 8 Cordyceps honeybee curing capsule is cleaned up influence (n=10, the x ± SD) of effect to mice carbon
| Group | Phagocytic index a | P |
| Matched group | 4.48±1.66 | |
| Low dose group | 4.80±1.22 | 0.893 |
| Middle dosage group | 4.46±1.26 | 1.000 |
| High dose group | 4.42±0.64 | 0.999 |
8, Cordyceps honeybee curing capsule is engulfed the influence of the phagocytic rate and the phagocytic index of chicken red blood cell to Turnover of Mouse Peritoneal Macrophages
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, the phagocytic rate of measuring, phagocytic index carry out homogeneity test of variance, satisfy the homogeneity of variance requirement, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Compared with matched group by visible basic, normal, high three the dosage groups of table 9 result, there are no significant for difference.
Table 9 Cordyceps honeybee curing capsule is engulfed influence (n=10, the x ± SD) of the phagocytic rate and the phagocytic index of chicken red blood cell to Turnover of Mouse Peritoneal Macrophages
| Group | Phagocytic rate (%) | P | Phagocytic index | P |
| Matched group | 20.3±4.7 | 0.24±0.07 | ||
| Low dose group | 23.3±9.2 | 0.617 | 0.30±0.11 | 0.322 |
| Middle dosage group | 22.9±5.7 | 0.710 | 0.28±0.08 | 0.587 |
| High dose group | 24.1±5.9 | 0.438 | 0.31±0.06 | 0.174 |
9, Cordyceps honeybee curing capsule is to the active influence of NK cells in mice
Per os gives the Cordyceps honeybee curing capsule 30 days of mice various dose, institute's measured value is carried out homogeneity test of variance, satisfy the homogeneity of variance requirement, carried out statistical disposition with the comparative approach in twos of mean between one factor analysis of variance method and a plurality of experimental group and matched group.Be significantly higher than matched group by the visible high dose group NK cells in mice of table 10 result activity.
Table 10 Cordyceps honeybee curing capsule is to the active influence of NK cells in mice (n=10, x ± SD)
| Group | NK cytoactive (%) | P |
| Matched group | 31.1±8.2 | |
| Low dose group | 35.1±6.8 | 0.496 |
| Middle dosage group | 26.1±6.9 | 0.296 |
| High dose group | 42.1±7.4 | 0.006 |
The specific embodiment
The invention will be further elaborated by the following examples.
Raw material sources that adopt among the embodiment and quality standard explanation:
Ganoderma extract prepares by following method: Ganoderma adds 8-12 times of water gaging after cutting into slices, and extracts 2-3 time, and each 4-6 hour, merge extractive liquid, concentrated the back spray drying; The prescription of Ganoderma extract is: polysaccharide 〉=8.0%, moisture≤8.0%, ash≤10.0%.Outward appearance is the dark-brown powder, drying, and free from admixture has the intrinsic fragrance of Ganoderma.
Embodiment 1
Get propolis 55g, Ganoderma extract 35g, Cordyceps mycelium 10g, Cordyceps mycelium is pulverized, and crosses 80 mesh sieves, with the Ganoderma extract mix homogeneously, 110-130 ℃ dry heat sterilization 1-2 hour, add again through pulverizing the propolis of 80 mesh sieves, add capsule adjuvant commonly used, mix homogeneously is made 1000 capsules by the capsule common process.
Embodiment 2
Propolis 50g, Ganoderma extract 40g, Cordyceps mycelium 10g, Cordyceps mycelium is pulverized, and crosses 80 mesh sieves, with the Ganoderma extract mix homogeneously, 110-130 ℃ dry heat sterilization 1-2 hour, add again through pulverizing the propolis of 80 mesh sieves, add tablet adjuvant commonly used, mix homogeneously is made 1000 by the tablet common process.
Embodiment 3
Propolis 60g, Ganoderma extract 30g, Cordyceps mycelium 10g, Cordyceps mycelium is pulverized, and crosses 80 mesh sieves, with the Ganoderma extract mix homogeneously, 110-130 ℃ dry heat sterilization 1-2 hour, add again through pulverizing the propolis of 80 mesh sieves, add granule adjuvant commonly used, mix homogeneously is made 1000 bag granules by the granule common process.
Embodiment 4
Propolis 55g, Ganoderma extract 30g, Cordyceps mycelium 15g, Cordyceps mycelium is pulverized, and crosses 80 mesh sieves, with the Ganoderma extract mix homogeneously, 110-130 ℃ dry heat sterilization 1-2 hour, add again through pulverizing the propolis of 80 mesh sieves, add capsule adjuvant commonly used, mix homogeneously is made 1000 capsules by the capsule common process.
Claims (4)
1. the health food of an enhancing immunity is characterized in that filling a prescription and contains the raw material of following weight portion:
Propolis 50-60 part, Ganoderma extract 30-40 part, Cordyceps mycelium 5-15 part;
Wherein Ganoderma extract prepares by following method: Ganoderma adds 8-12 times of water gaging after cutting into slices, and extracts 2-3 time, and each 4-6 hour, merge extractive liquid, concentrated the back spray drying; The prescription of Ganoderma extract is: polysaccharide 〉=8.0%, moisture≤8.0%, ash≤10.0%.
2. health food according to claim 1 is characterized in that its preparation is any one dosage form that pharmaceutically allows.
3. health food according to claim 2 is characterized in that its dosage form is tablet, granule, capsule, oral liquid, syrup or pill.
4. the preparation technology of health food as claimed in claim 1 is characterized in that comprising the following step:
Get Cordyceps mycelium by prescription and pulverize, cross 80 mesh sieves, with the Ganoderma extract mix homogeneously, 110-130 ℃ dry heat sterilization 1-2 hour, add again through pulverizing the propolis of 80 mesh sieves, mix homogeneously, common process are made required preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100956302A CN100420448C (en) | 2005-11-25 | 2005-11-25 | Health-care food with function for improving immunity and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100956302A CN100420448C (en) | 2005-11-25 | 2005-11-25 | Health-care food with function for improving immunity and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1785055A CN1785055A (en) | 2006-06-14 |
| CN100420448C true CN100420448C (en) | 2008-09-24 |
Family
ID=36782733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100956302A Expired - Fee Related CN100420448C (en) | 2005-11-25 | 2005-11-25 | Health-care food with function for improving immunity and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100420448C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218084A (en) * | 2011-06-08 | 2011-10-19 | 华夏先葆(北京)中药研究院有限公司 | Traditional Chinese medicament health preserving preparation having effects of enhancing immunity, resisting ageing and improving sub-health |
| WO2019024012A1 (en) * | 2017-08-02 | 2019-02-07 | 江苏安惠生物科技有限公司 | Capsule for enhancing immunity and improving sleep |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100452991C (en) * | 2006-09-13 | 2009-01-21 | 聂承和 | Health care food with enhancing human body immunity, fatigue resistant and radioresistant function and making method thereof |
| CN103230003B (en) * | 2013-04-22 | 2015-01-07 | 吉林修正药业新药开发有限公司 | Health food with immunity boosting function and preparation method thereof |
| CN103859394B (en) * | 2014-01-16 | 2016-05-25 | 安徽工程大学 | Formula of mountain, a kind of Kaohsiung cordyceps mycelia propolis oral liquid and preparation method thereof |
| CN105012780A (en) * | 2015-07-03 | 2015-11-04 | 广西大学 | Coix seed oil health care capsule |
| CN105638931A (en) * | 2016-01-07 | 2016-06-08 | 伊国群 | Compound natural and nutritional health product capable of enhancing immunity |
| CN106666592A (en) * | 2016-12-23 | 2017-05-17 | 程艳青 | Health product for old people with effects for supplementing calcium, and regulating blood lipid and blood pressure |
| CN108653569A (en) * | 2018-06-26 | 2018-10-16 | 吕军 | It is a kind of for kidney tonifying, sleeping, toxin expelling health products and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520877A (en) * | 2003-02-13 | 2004-08-18 | 萍 陈 | Preparing process for nutrition and health capsule |
| CN1524436A (en) * | 2003-02-27 | 2004-09-01 | 谢钧谟 | Body-building health-care food composition and its preparation method |
| CN1660388A (en) * | 2004-12-14 | 2005-08-31 | 南京中科生化技术有限公司 | Oral Chinese material medica preparation for regulating blood sugar and improving immunologic function and preparation method |
-
2005
- 2005-11-25 CN CNB2005100956302A patent/CN100420448C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520877A (en) * | 2003-02-13 | 2004-08-18 | 萍 陈 | Preparing process for nutrition and health capsule |
| CN1524436A (en) * | 2003-02-27 | 2004-09-01 | 谢钧谟 | Body-building health-care food composition and its preparation method |
| CN1660388A (en) * | 2004-12-14 | 2005-08-31 | 南京中科生化技术有限公司 | Oral Chinese material medica preparation for regulating blood sugar and improving immunologic function and preparation method |
Non-Patent Citations (4)
| Title |
|---|
| 中草药免疫增强剂的研究与应用. 刘欣.辽宁畜牧兽医，第2期. 2004 |
| 中草药免疫增强剂的研究与应用. 刘欣.辽宁畜牧兽医，第2期. 2004 * |
| 蜂制品与真菌多糖的复配. 顾顺明等.中国养蜂，第55卷第5期. 2004 |
| 蜂制品与真菌多糖的复配. 顾顺明等.中国养蜂，第55卷第5期. 2004 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218084A (en) * | 2011-06-08 | 2011-10-19 | 华夏先葆(北京)中药研究院有限公司 | Traditional Chinese medicament health preserving preparation having effects of enhancing immunity, resisting ageing and improving sub-health |
| WO2019024012A1 (en) * | 2017-08-02 | 2019-02-07 | 江苏安惠生物科技有限公司 | Capsule for enhancing immunity and improving sleep |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1785055A (en) | 2006-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100420448C (en) | Health-care food with function for improving immunity and its prepn. method | |
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN101485463B (en) | Natural product composing prescription with various health-care efficacies | |
| CN106064993A (en) | The culture medium of a kind of Hericium erinaceus (Bull. Ex Fr.) Pers., bioconversion mycelium, the mycelial extract of bioconversion and application thereof | |
| CN104352552A (en) | Food, health care product or medicine composition | |
| CN101991744B (en) | Traditional Chinese medicine perfusion agent for treating milk cow endometritis | |
| CN105125946A (en) | Gardenia oral liquid clearing away heart fire and relieving restlessness and preparing method thereof | |
| CN103690573B (en) | A kind of natural drug composition for strengthen immunity and preparation method thereof | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN100544736C (en) | A kind of pharmaceutical composition of enhancing immunity and preparation method | |
| CN106668077A (en) | Marine bioactive composition and pharmaceutical preparation | |
| CN106214844A (en) | A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof | |
| CN101537079B (en) | Pharmaceutical composition or health-care product for improving sleeping and delaying senility and preparation method thereof | |
| CN101912439B (en) | Technology for extracting Chinese angelica and lightyellow sophora root | |
| CN1994335A (en) | Preparation method of detoxification tablet with toad and poria | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN105521327B (en) | Medicinal composition for preventing and/or curinng alcoholic liver disease or liver cancer | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN1981845B (en) | Chinese-medicinal composition, its production and use | |
| CN107693752A (en) | A kind of oral products and preparation method for psoriasis | |
| CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
| CN115245549B (en) | Traditional Chinese medicine composition for improving gouty arthritis with damp-heat constitution | |
| CN102423384A (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN1927273A (en) | Bath agent for influenza defervesce and preparing method thereof | |
| CN108452240A (en) | A kind of antitumor Chinese medicine composition and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Anhui Huangshan Yunle Glossy Ganoderma Co., Ltd. Assignor: Nanjing Zhongke Group Co., Ltd. Contract record no.: 2010340000181 Denomination of invention: Health-care food with function for improving immunity and its prepn. method Granted publication date: 20080924 License type: Exclusive License Open date: 20060614 Record date: 20100925 |
|
| ASS | Succession or assignment of patent right |
Owner name: NANJING ZHONGKE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANJING ZHONGKE GROUP CO., LTD. Effective date: 20110321 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210008 20/F, HEPING BUILDING, NO. 22, BEIJING EAST ROAD, NANJING CITY, JIANGSU PROVINCE TO: 211102 NO. 8, ZHONGKE ROAD, JIANGNING ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, NANJING CITY, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110321 Address after: Nanjing City, Jiangsu Province Branch Road 211102 Jiangning economic and Technological Development Zone No. 8 Patentee after: Nanjing Zhongke Pharmaceutical Co., Ltd. Address before: 210008, Heping building, No. 22, Beijing East Road, Jiangsu, Nanjing, 20 Patentee before: Nanjing Zhongke Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080924 Termination date: 20141125 |
|
| EXPY | Termination of patent right or utility model |